Alnylam Pharmaceuticals
ALNY
374 hedge funds and large institutions have $16.5B invested in Alnylam Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 74 funds opening new positions, 137 increasing their positions, 109 reducing their positions, and 28 closing their positions.
164% more first-time investments, than exits
New positions opened: 74 | Existing positions closed: 28
40% more capital invested
Capital invested by funds: $11.8B → $16.5B (+$4.72B)
38% more call options, than puts
Call options by funds: $154M | Put options by funds: $111M
26% more repeat investments, than reductions
Existing positions increased: 137 | Existing positions reduced: 109
13% more funds holding
Funds holding: 330 → 374 (+44)
1.28% more ownership
Funds ownership: 95.96% → 97.24% (+1.3%)
0% more funds holding in top 10
Funds holding in top 10: 8 → 8 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$186M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
+$143M |
| 3 |
Blackstone Inc
New York
|
+$125M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$79.6M |
| 5 |
BlackRock
New York
|
+$74.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$245M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$60.7M |
| 3 |
Dodge & Cox
San Francisco,
California
|
-$52.5M |
| 4 |
MC
Maverick Capital
Dallas,
Texas
|
-$30.5M |
| 5 |
AG
Artal Group
Luxembourg
|
-$27M |
ALNY Hedge Fund Activity: Q2 2020 in Review
374 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in Alnylam Pharmaceuticals (ALNY) for Q2 2020, worth a combined $16.5B — up 40% from $11.8B a quarter earlier.
Buyers outnumbered sellers: 74 funds opened new ALNY positions and 28 closed out — a net gain of 46 holders — while 137 added to existing stakes and 109 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $186M. The largest seller was Wellington Management Group, cutting an estimated $245M.
- 374 institutional investors held Alnylam Pharmaceuticals (ALNY) as of Q2 2020, up from 330 in Q1 2020.
- Funds reported $16.5B of Alnylam Pharmaceuticals stock for Q2 2020, up 40% quarter-over-quarter.
- 74 funds opened new Alnylam Pharmaceuticals positions in Q2 2020 and 28 closed out, a net change of +46 holders.
- The largest Alnylam Pharmaceuticals buyer in Q2 2020 was JP Morgan Chase, an estimated $186M added.
- The largest Alnylam Pharmaceuticals seller in Q2 2020 was Wellington Management Group, an estimated $245M sold.
Based on aggregated 13F filings for Q2 2020.